Calculate Your Salary Ranking
Home > Avi Biopharma Salary

Avi Biopharma Salary
  • 86
  • 64
  • 27

Avi Biopharma average salary is $33,000, median salary is $33,000 with a salary range from $33,000 to $33,000.
Avi Biopharma salaries are collected from government agencies and companies. Each salary is associated with a real job position. Avi Biopharma salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 1 Avi Biopharma Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Postdoctorate, Scientist 33,000-33,000 Corvallis, OR, 97330 2010 Avi Biopharma Postdoctorate, Scientist Salaries (1)
Avi Biopharma Corvallis, OR Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Avi Biopharma Salaries (February 22, 2017)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Avi Biopharma salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Avi Biopharma Information
  • AVI BioPharma, Inc
  • Industry: BioTech/Drugs
  • City: Bothell, WA
  • AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: NEUGENE antisense drugs and cancer immunotherapy. Its lead cancer agent, AVICINE(R), a therapeutic cancer vaccine, has completed three Phase II trials in colorectal and pancreatic cancer and is in a Phase III pivotal trial in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG(TM), is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene c-myc. It is currently in Phase II trials for restenosis and in Phase I/II trials for cancer